FIELD: biochemistry.
SUBSTANCE: invention relates to the field of biochemistry, in particular to an antibody directed against CD4 molecule. A pharmaceutical composition containing the specified antibody, methods for HIV treatment, methods for the inhibition of HIV entry, inhibition of gp120 binding to CD4+ cell, a method for activating a resting CD4+ T-cell, and a method for activating latent HIV reservoir in a resting T-cell using the specified antibody or a pharmaceutical composition are also disclosed.
EFFECT: invention allows for the effective treatment of HIV-infection.
60 cl, 46 dwg, 27 tbl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DERIVATIVES OF PROTEIN FUSED WITH Fc WITH HIGH DOUBLE ACTIVITY: ANTIVIRAL ACTIVITY RELATIVELY TO HIV AND IMMUNOMODULATING ACTIVITY | 2018 |
|
RU2774782C2 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| HIV ANTIBODY COMPOSITIONS AND METHODS FOR THEIR APPLICATION | 2016 |
|
RU2757135C2 |
| NEW ANTIBODIES AND NUCLEOTIDE SEQUENCES AND THEIR USE | 2019 |
|
RU2802450C2 |
| HIV-1 SUBTYPE A P17 PROTEIN ANTIBODIES | 2019 |
|
RU2727673C1 |
| OX40 BINDING POLYPEPTIDES AND THEIR USE | 2019 |
|
RU2802070C2 |
| ANTIBODY MOLECULES THAT BIND CD137 AND OX40 | 2019 |
|
RU2817602C2 |
| METHODS FOR PRODUCTION OF COMPOSITIONS OF GENETICALLY ENGINEERED CELLS AND RELATED COMPOSITIONS | 2018 |
|
RU2790444C2 |
| COMBINATION OF CELL THERAPY AND IMMUNOMODULATOR COMPOUND | 2018 |
|
RU2777911C2 |
| PRODUCTION OF CONSTRUCTED CELLS FOR ADOPTIVE CELL THERAPY | 2017 |
|
RU2780156C2 |
